Welcome to our dedicated page for Mind Medicine SEC filings (Ticker: MNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates for brain health disorders, and its filings offer detailed information on clinical progress, financing transactions and corporate matters.
Through Forms 8‑K, MindMed reports material events such as underwritten public offerings of common shares under its shelf registration statement on Form S‑3, entry into underwriting agreements, and the intended use of proceeds to fund research and development, working capital and general corporate purposes. Other 8‑K filings describe the release of quarterly financial results, updated corporate presentations, and announcements related to clinical and scientific milestones, including publication of MM120 trial data in generalized anxiety disorder.
MindMed’s filings also identify its jurisdiction of incorporation in British Columbia, Canada, its listing of common shares on The Nasdaq Stock Market LLC under the symbol MNMD, and its status as an emerging growth company. Investors can use this page to review prospectus supplements, opinions and exhibits referenced in 8‑K filings, as well as periodic reports such as Forms 10‑K and 10‑Q accessed via EDGAR.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, such as the terms of public offerings, changes in cash and investments, and updates on the development of MM120 and MM402. Real-time updates from EDGAR, along with structured access to Forms 10‑K, 10‑Q and 4, help users quickly locate information on MindMed’s financial condition, capital structure and insider-related disclosures.
Definium Therapeutics, Inc. Chief Medical Officer Daniel Karlin reported an open-market sale of 8,018 Common Shares on March 25, 2026 at a weighted average price of $18.47 per share. According to the footnotes, these shares were sold to satisfy withholding tax obligations tied to the settlement of vested restricted stock units under a Rule 10b5-1 sell-to-cover plan adopted on June 14, 2022.
After this transaction, Karlin directly owns 413,317 Common Shares, which includes 1,586 shares acquired through the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan. This filing reflects a tax-related, pre-planned disposition rather than a discretionary sale of a large ownership stake.
Definium Therapeutics, Inc. Chief Legal Officer Mark Sullivan sold 10,702 Common Shares on March 25, 2026 at a weighted average price of $18.47. According to the filing, the shares were sold to satisfy withholding tax obligations tied to vested restricted stock units under a Rule 10b5-1 sell-to-cover plan adopted on March 14, 2024. Following this tax-related sale, he directly holds 271,079 Common Shares, which includes 793 shares acquired under the company’s 2024 Employee Share Purchase Plan.
Definium Therapeutics, Inc. Chief Executive Officer Robert Barrow reported an open-market sale of 24,431 Common Shares at a weighted average price of $18.47 per share. The shares were sold to satisfy withholding tax obligations linked to vested restricted stock units under a Rule 10b5-1 sell-to-cover plan adopted on June 15, 2022.
Following this transaction, Barrow directly holds 752,454 Common Shares, and this amount includes 1,586 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan. Because the sale was for tax withholding under a pre-planned trading arrangement, it reflects a routine administrative event rather than a discretionary change in ownership.
Robert Barrow filed a Form 144 reporting an intended sale of 24,431 shares of Common stock of DFTX on 03/25/2026, described as restricted stock vesting under a registered plan. The filing also shows a prior sale of 25,791 shares on 12/26/2025.
Daniel Karlin filed a Form 144 reporting 8,018 shares of Common Stock to be sold on 03/25/2026. The filing states the shares relate to restricted stock vesting under a registered plan and lists the disposition as Issuer with reason "Services Rendered". The form also shows 5,600 shares sold on 12/26/2025 with proceeds of $73,622.00.
Mark Sullivan reports intent to sell 10,702 shares of Common Stock on 03/25/2026. The filing lists the shares as restricted stock vesting under a registered plan and identifies the transaction as involving the issuer. The filing also discloses a prior sale of 11,276 shares on 12/26/2025.
Definium Therapeutics reported a larger full-year 2025 net loss of $183.8 million, compared with $108.7 million in 2024, as it ramped late-stage development for its psychedelic-based therapies.
Cash, cash equivalents and investments rose to $411.6 million as of December 31, 2025, up from $273.7 million a year earlier, helped by a $259 million equity financing completed in the fourth quarter. The company expects this cash to fund operations into 2028.
Research and development expenses increased to $117.7 million from $65.3 million, driven mainly by higher DT120 program spending and expanded R&D staffing. General and administrative costs rose to $48.6 million from $38.6 million, reflecting greater professional services, pre-commercial efforts, and personnel expenses.
Definium highlighted progress across four Phase 3 trials of DT120 ODT in major depressive disorder and generalized anxiety disorder, with its Emerge MDD study fully enrolled and multiple topline readouts anticipated in 2026. It also advanced DT402 into a Phase 2a study for autism spectrum disorder.
Definium Therapeutics, Inc. has a large shareholder group led by Commodore Capital LP reporting beneficial ownership of 7,428,775 common shares, representing 7.2% of the company as of December 31, 2025. This position includes 2,000,000 common shares plus 5,428,775 shares that can be acquired through a pre-funded warrant, which is subject to a 9.99% beneficial ownership limitation. The ownership percentage is based on 98,509,279 common shares reported outstanding as of October 31, 2025, plus the warrant shares. The filing is made jointly by Commodore Capital LP, Commodore Capital Master LP, and managing partners Robert Egen Atkinson and Michael Kramarz, who certify that the securities are not held for the purpose of changing or influencing control of the issuer. The issuer recently changed its name from Mind Medicine (MindMed) Inc. to Definium Therapeutics, Inc.
Driehaus Capital Management LLC, a Delaware investment adviser, reported beneficial ownership of Definium Therapeutics, Inc. common stock. Driehaus has shared voting and dispositive power over 6,537,202 shares, representing 6.64% of the company’s common stock as of the event date.
The shares are held in numerous fully discretionary client accounts managed by Driehaus, which reports potential voting and dispositive power, while clients generally do not hold more than 5% of the class individually. Driehaus states the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Definium Therapeutics.
Avoro Capital Advisors LLC and Behzad Aghazadeh have reported a new significant ownership position in Definium Therapeutics, Inc. They beneficially own 5,000,000 Common Shares, representing 5.08% of the class, with sole voting and dispositive power over these shares.
The ownership percentage is based on 98,509,279 Common Shares outstanding as of October 31, 2025, as referenced from the company’s Form 10-Q for the quarter ended September 30, 2025. The investors state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.